Victoria Forster, PhD

Victoria Forster is a postdoctoral research scientist and freelance science writer. Her research interests include; DNA repair deficiencies, pediatric cancers, stem cell and organoid models for cancer development and cancer treatment-related side effects. She is also a 25-year survivor of childhood leukemia and an advocate for childhood cancer awareness. She has bylines in several outlets including The Times, The Guardian, Forbes, and Cancer Therapy Advisor.

All articles by Victoria Forster, PhD

Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.

General Oncology

Drug Shortages Threaten Childhood Cancer Treatment

Victoria Forster, PhD

April 1, 2019

Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.

Skin Cancer

TVEC for Advanced Melanoma Yields Stunning Results in 3-Center Study

Victoria Forster, PhD

March 20, 2019

Could combining the oncolytic viral therapy TVEC with other therapies enhance the immunotherapy’s efficacy, allowing more patients to benefit?

Chronic Myeloid Leukemia, Hematologic Cancers

Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML

Victoria Forster, PhD

February 28, 2019

Although patients with CML may not be eligible for TKI discontinuation based on transcript alone, the type of transcript seen may have some implications for loss of treatment remission.

Researchers identified 15 genes that they said independently predict the survival outcome of patient

Renal Cell Carcinoma

Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome

Victoria Forster, PhD

February 12, 2019

Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.

Researchers provide further proof that CRISPR can augment cancer treatment in the lab, but many barr

Lung Cancer

CRISPR in Cancer: Not Quite Ready for Clinical Trials

Victoria Forster, PhD

January 24, 2019

Researchers provide further proof that CRISPR can augment cancer treatment in the lab, but many barriers remain before clinical trials can be conducted in patients.

Next post in Lung Cancer

Victoria Forster, PhD

All articles by Victoria Forster, PhD

Drug Shortages Threaten Childhood Cancer Treatment

TVEC for Advanced Melanoma Yields Stunning Results in 3-Center Study

Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML

Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome

CRISPR in Cancer: Not Quite Ready for Clinical Trials

Improved Disease-Free Survival With Adjuvant Erlotinib in EGFR-Mutant, Early-Stage NSCLC